Salmonella based oral vaccines for anthrax

Details Salmonella based oral vaccines for anthrax Salmonella based oral vaccines for anthrax

2011-05-24

2011-05-24

Duffy, Patricia A (Department: 1645)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093400, C435S252300

Reexamination Certificate

active

07947268

ABSTRACT:
A vaccine for the prevention of anthrax, including a live, attenuatedSalmonellaand at least one nucleotide sequence encoding anthrax protective antigen (PA) or a fragment thereof and a nonlethal mutated form of anthrax lethal factor (LF) or a fragment thereof. In another implementation, the vaccine is constituted for the prevention of anthrax and at least one additional pathogen, as including a live, attenuatedSalmonellaand at least one nucleotide sequence encoding at least a fragment of a nonlethal mutated form of anthrax lethal factor (LF) and at least one nucleotide sequence encoding at least a fragment of an antigen of an additional pathogen. Vaccines of such types can be administered to stimulate antibody response in a subject, whereby the antibody response confers immunity to the subject.

REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 6576757 (2003-06-01), Punnonen et al.
patent: 6979449 (2005-12-01), Mock
patent: 2003/0003109 (2003-01-01), Galloway et al.
patent: 2004/0009936 (2004-01-01), Tang et al.
patent: 2004/0166120 (2004-08-01), Thomas et al.
patent: 2004/0197343 (2004-10-01), Dubensky, Jr. et al.
patent: 2005/0063986 (2005-03-01), Bhatnagar et al.
patent: 2005/0064391 (2005-03-01), Segal et al.
patent: 2005/0112145 (2005-05-01), Hudson et al.
patent: 0145639 (2001-06-01), None
patent: 0204646 (2002-01-01), None
patent: 2005026203 (2005-03-01), None
Gustafsson et al (Trends in Biotechnology, 22(7):346-353, Jul. 2004).
Dempsey et al (Science, 271(5247):348-350, 1996).
Aloni-Grinstein, R., et al., “Oral Spore Vaccine Based on Live Attenuated NontoxinogenicBacillus anthracisExpressing Recombinant Mutant Protective A”, “Infect. Immun.”, Jul. 2005, pp. 4043-4053, vol. 73, No. 7.
Baillie, L.W., et al., “Abstract Only: Evaluation ofBacillus subtilisstrain IS53 for the production ofBacillus anthracisprotective antigen”, “Lett. Appl. Microbiol.”, Oct. 1994, pp. 225-227, vol. 19, No. 4.
Baillie, L., et al., “The expression of the protective antigen ofBacillus anthracisinBacillus subtilis”, “Journal of Applied Microbiology”, 1998, pp. 741-746, vol. 84.
Baillie, L. W., et al., “Abstract Only: A heat-inducibleBacillus subtilisbacteriophage phi 105 expression system for the production of the . . . ”, “FEMS Microbiology Lett.”, Jun. 1, 1998, pp. 43-47, vol. 163, No. 1.
Baillie, L., “The development of new vaccines againstBacillus anthracis”, “Journal of Applied Microbiology”, 2001, pp. 609-613, vol. 91.
Baillie, L., et al., “Abstract Only:Bacillus anthracis, a bug with attitude!”, “Cum. Opin. Microbiol.”, eb. 2001, pp. 78-81, vol. 4, No. 1.
Baillie, Leslie, et al., “Abstract Only: Characterization of the human immune response to the U.K. human vaccine”, “FEMS Immunoology and Medical Microbiology”, 2004, pp. 267-270, vol. 42.
Ballard, Jimmy D., et al., “Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo”, “Proc. Natl. Acad. Sci.”, Oct. 1996, pp. 12531-12534, vol. 93.
Ballard, Jimmy D., et al., “Anthrax Toxin as a Molecular Tool for Stimulation of Cytotoxic T Lymphocytes: Disulfide-Linked Epitopes, Multiple Inject”, “Infect. Immun.”, Oct. 1998, pp. 4696-4699, vol. 66, No. 10.
Ballard, Jimmy D., et al., “Anthrax Toxin-Mediated Delivery in Vivo and in Vitro of a Cytotoxic T-Lymphocyte Epitope from Ovalbumin”, “Infect. Immun.”, Feb. 1998, pp. 615-619, vol. 66, No. 2.
Cao, H., et al., “Abstract Only: Delivery of exogenous protein antigens to major historcompatibility complex class I pathway in cytosol”, “J. Infect. Dis.”, Jan. 15, 2002, pp. 244-251, vol. 185, No. 1.
Curtiss, Roy III, “Bacterial infectious disease control by vaccine development”, “The Journal of Clinical Investigation”, 2002, pp. 1061-1066, vol. 110, No. 8.
Doling, Amy M., et al., “Cytotoxic T-Lymphocyte Epitopes Fused to Anthrax Toxin Induce Protective Antiviral Immunity ”, “Infect. Immun.”, Jul. 1999, pp. 3290-3296, vol. 67, No. 7.
Flick-Smith, Helen C., et al., “Mucosal or Parenteral Administration of Microsphere-AssociatedBacillus anthracisProtective Antigen Protects . . . ”, “Infect. Immun.”, Apr. 2002, pp. 2022-2028, vol. 70, No. 4.
Flick-Smith, Helen C., et al., “A recominant carboxy-terminal domain of the protective antigen ofBacillus anthracisprotects mice against anthrax . . . ”, “Infect. Immun.”, Mar. 2002, pp. 1653-1656, vol. 70, No. 3.
Galen, James E., et al., “Adaptation of the endogenousSalmonella entericaserovar Typhi clyA-encoded hemolysin for antigen export enhances . . . ”, “Infect. Immun.”, Dec. 2004, pp. 7096-7106, vol. 72, No. 12.
Galloway, D., et al., “Abstract Only: Genetic immunization against anthrax”, “Vaccine”, Apr. 16, 2004, pp. 1604-1608, vol. 22, No. 13-14.
Garmory, Helen S., et al., “Salmonella entericaserovar typhimurium expressing a chromosomally integrated copy of theBacillus anthracis. . . ”, “Infect. Immun.”, Jul. 2003, pp. 3831-3836, vol. 71, No. 7.
Hermanson, G., et al., “A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized . . . ”, “PNAS”, Sep. 14, 2004, pp. 13601-13606, vol. 101, No. 37.
Hoffmaster, Alex R., et al., “Identification of anthrax toxin genes in aBacillus cereusassociated with an illness resembling inhalation anthrax”, “PNAS”, Jun. 1, 2004, pp. 8449-8454, vol. 101, No. 22.
Kang, Tae Jin, et al., “Murine Macrophages Kill the Vegetative Form ofBacillus anthracis”, “Infect. lmmun.”, Nov. 2005, pp. 7495-7501, vol. 73, No. 11.
Klimpel, K.R., et al., “Abstract Only: Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required . . . ”, “Mol. Microbiol.”, Sep. 1994, pp. 1093-1100, vol. 13, No. 6.
Kushner, Nicholas, et al., “A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen”, “PNAS”, May 27, 2003, pp. 6652-6657, vol. 100, No. 11.
Lim, Nam-Kyu, et al., “An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin”, “Infect. Immun.”, Oct. 2005, pp. 6547-6551, vol. 73, No. 10.
Lu, Yichen, et al., “Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell . . . ”, “PNAS”, Jul. 5, 2000, pp. 8027-8032, vol. 97, No. 14.
McBride, B. W., et al., “Abstract Only: Protective efficacy of a recombinant protective antigen againstBacillus anthracischallenge and . . . ”, “Vaccine”, May 1998, pp. 810-817, vol. 16, No. 8.
Miller, J., et al., “Abstract Only: Production and purification of recombinant protective antigen and protective efficacy againstBacillus. . . ”, “Lett. Appl. Microbiol.”, Jan. 1998, pp. 56-60, vol. 26, No. 1.
Petosa, C., et al., “Abstract Only: Crystal structure of the anthrax toxin protective antigen”, “Nature”, Feb. 27, 1997, pp. 833-838, vol. 385, No. 6619.
Pezard, Corinne, et al., “Protective immunity induced byBacillus anthracistoxin-deficient strains”, “Infect. Immun.”, Apr. 1995, pp. 1369-1372, vol. 63, No. 4.
Pomerantsev, A. P., et al., “Abstract Only: Expression of cereolysine AB genes inBacillus anthracisvaccine strain ensures protection against . . . ”, “Vaccine”, Dec. 1997, pp. 1846-1850, vol. 15, No. 17-18.
Price, Brian M., et al., “Protection against Anthrax Lethal Toxin Challenge by

Affiliated with

Also associated with

Rating

Salmonella based oral vaccines for anthrax does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Salmonella based oral vaccines for anthrax, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salmonella based oral vaccines for anthrax will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680374